Tango Therapeutics, Inc. (TNGX)
| Market Cap | 4.26B +473.5% |
| Revenue (ttm) | 53.81M +121.5% |
| Net Income | -123.72M |
| EPS | -0.91 |
| Shares Out | 168.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,037,413 |
| Open | 25.39 |
| Previous Close | 25.47 |
| Day's Range | 25.24 - 26.85 |
| 52-Week Range | 6.25 - 34.39 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 44.75 (+77.02%) |
| Earnings Date | Aug 11, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $44.75, which is an increase of 77.02% from the latest price.
News
Tango Therapeutics price target raised to $68 from $66 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Tango Therapeutics (TNGX) to $68 from $66 and keeps a Buy rating on the shares following the Q2 report.
Tango Therapeutics price target raised to $35 from $32 at Guggenheim
Guggenheim raised the firm’s price target on Tango Therapeutics (TNGX) to $35 from $32 and keeps a Buy rating on the shares to account for Q2 updates and trends as…
Tango Therapeutics reports Q2 EPS (37c), consensus (32c)
“The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our maturing organization. Notably, initial Phase 1/2 dat...
Tango Therapeutics Quarterly report: Q2 2026
Tango Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Tango Therapeutics Earnings release: Q2 2026
Tango Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Tango Therapeutics executive chairman Weber to step down
Tango Therapeutics (TNGX) announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits. “I am…
Tango Therapeutics Announces Executive Chair Transition
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics price target raised to $40 from $36 at Mizuho
Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $36 and keeps an Outperform rating on the shares. The firm believes Revolution Medicines’ (RVMD) data for…
Tango Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Tango Therapeutics (TNGX) with an Overweight rating and $46 price target The firm says Tango is “leading the way” in pancreatic ductal adenocarcinoma...
Tango Therapeutics price target raised to $46 from $42 at Canaccord
Canaccord raised the firm’s price target on Tango Therapeutics (TNGX) to $46 from $42 and keeps a Buy rating on the shares. The firm said they see additional upside for…
Tango Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies upgraded Tango Therapeutics (TNGX) to Buy from Hold with a price target of $60, up from $27. Although the stock is up 242% year-to-date, the firm argues that additional…
Tango Therapeutics Appoints Robert Azelby to Board of Directors
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics 18.2M share Secondary priced at $30.00
The deal size was increased to $600M in common stock from $500M in common stock. JPMorgan, Leerink, Cantor Fitzgerald and Stifel acted as joint book running managers for the offering.
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of preci...
Tango Therapeutics price target raised to $66 from $27 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tango Therapeutics (TNGX) to $66 from $27 and keeps a Buy rating on the shares after the company announced initial Phase 1…
Tango Therapeutics price target raised to $42 from $30 at Canaccord
Canaccord raised the firm’s price target on Tango Therapeutics (TNGX) to $42 from $30 and keeps a Buy rating on the shares. The firm updated its model following results that…
Tango Therapeutics announces $500M common stock offering
Tango Therapeutics (TNGX) announced the launch of an underwritten public offering of $500M of its common stock. All shares of common stock to be sold in the offering will be…
Tango Therapeutics Announces Proposed $500 Million Public Offering
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of preci...
Tango Therapeutics stock soars on promising pancreatic cancer data
Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, ...
Tango Therapeutics price target raised to $69 from $55 at Leerink
Leerink raised the firm’s price target on Tango Therapeutics (TNGX) to $69 from $55 and keeps an Outperform rating on the shares after the company provided details from its ongoing…
Tango Therapeutics price target raised to $36 from $30 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Tango Therapeutics (TNGX) to $36 from $30 and keeps an Outperform rating on the shares following this morning’s topline disclosure…
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.
Tango Therapeutics' pancreatic cancer drug combo shows promise in study
Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients with advanced pancreatic cancer and that it plans to advance the treatment ...
Tango Therapeutics Transcript: Study result
Combination of vopimetostat with pan-RAS inhibitors in MTAP-deleted pancreatic cancer showed a 92% response rate and 90% six-month PFS, with strong durability and tolerability. Plans include a phase III trial in first-line patients and expansion into other cancers.
Tango Therapeutics Press release: Study result
Tango Therapeutics issued a press release on June 8, 2026, disclosing material business information to investors.